Circovirus sequences associated with piglet weight loss disease (PWD)
View Patent ↗The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors; methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided; method for selecting compounds capable of modulating the viral infection is further provided; and pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1. A vector capable of expressing at least one polypeptide encoded by a nucleic acid sequence comprising a sequence having at least 90% sequence identity to SEQ. ID. NO: 15, wherein said nucleic acid sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
2. The vector of claim 1 , wherein the vector is a baculovirus vector.
3. A vector capable of expressing at least one polypeptide encoded by a nucleic acid sequence comprising a sequence having at least 95% sequence identity to SEQ. ID. NO:15, wherein said nucleic acid sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
4. The vector of claim 3 , wherein the vector is a baculovirus vector.
5. A vector capable of expressing at least one polypeptide encoded by a nucleic acid sequence comprising a sequence having at least 90% sequence identity to SEQ. ID. NO: 15, wherein said nucleic acid sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
6. The vector of claim 5 , wherein the vector is a baculovirus vector.
7. A vector capable of expressing at least one polypeptide encoded by a nucleic acid sequence comprising a sequence having at least 95% sequence identity to SEQ. ID. NO: 15, wherein said nucleic acid sequence comprises a sequence having at least 95% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
8. The vector of claim 7 , wherein the vector is a baculovirus vector.
9. A vaccine composition, comprising the vector of claim 1 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
10. A vaccine composition, comprising the vector of claim 2 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
11. A vaccine composition, comprising the vector of claim 3 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
12. A vaccine composition, comprising the vector of claim 4 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
13. A vaccine composition, comprising the vector of claim 5 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
14. A vaccine composition, comprising the vector of claim 6 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
15. A vaccine composition, comprising the vector of claim 7 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
16. A vaccine composition, comprising the vector of claim 8 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
17. An immunogenic composition, comprising an immunizing amount of the vector of claim 1 and a pharmaceutically or veterinarily acceptable carrier.
18. An immunogenic composition, comprising an immunizing amount of the vector of claim 2 and a pharmaceutically or veterinarily acceptable carrier.
19. An immunogenic composition, comprising an immunizing amount of the vector of claim 3 and a pharmaceutically or veterinarily acceptable carrier.
20. An immunogenic composition, comprising an immunizing amount of the vector of claim 4 and a pharmaceutically or veterinarily acceptable carrier.
21. An immunogenic composition, comprising an immunizing amount of the vector of claim 5 and a pharmaceutically or veterinarily acceptable carrier.
22. An immunogenic composition, comprising an immunizing amount of the vector of claim 6 and a pharmaceutically or veterinarily acceptable carrier.
23. An immunogenic composition, comprising an immunizing amount of the vector of claim 7 and a pharmaceutically or veterinarily acceptable carrier.
24. An immunogenic composition, comprising an immunizing amount of the vector of claim 8 and a pharmaceutically or veterinarily acceptable carrier.
25. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 9 .
26. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 10 .
27. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 11 .
28. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 12 .
29. A method for treating or preventing Porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 13 .
30. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 14 .
31. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 15 .
32. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 16 .
33. A recombinant polynucleotide comprising a sequence having at least 90% sequence identity to SEQ ID NO:15, wherein said nucleic acid sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
34. A recombinant polynucleotide comprising a sequence having at least 95% sequence identity to SEQ ID NO:15, wherein said nucleic acid sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
35. A recombinant polynucleotide comprising a sequence having at least 90% sequence identity to SEQ ID NO: 15, wherein said nucleic acid sequence comprises a sequence having at least 95% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
36. A recombinant polynucleotide comprising a sequence having at least 95% sequence identity to SEQ ID NO: 15, wherein said nucleic acid sequence comprises a sequence having at least 95% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
37. A method for detecting and quantifying at least one polynucleotide of a porcine circovirus type B (PCVB) by a hybridization method, wherein said polynucleotide comprises a sequence with at least 90% identity to SEQ ID NO: 15, wherein said nucleic acid sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
38. A method for detecting and quantifying at least one polynucleotide of a porcine circovirus type B (PCVB) by a hybridization method, wherein said polynucleotide comprises a sequence with at least 90% identity to SEQ ID NO: 15, wherein said nucleic acid sequence comprises a sequence having at least 95% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
39. A method for detecting and quantifying at least one polynucleotide of a porcine circovirus type B (PCVB) by a hybridization method, wherein said polynucleotide comprises a sequence with at least 95% identity to SEQ ID NO: 15, wherein said nucleic acid sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
40. A method for detecting and quantifying at least one polynucleotide of a porcine circovirus type B (PCVB) by a hybridization method, wherein said polynucleotide comprises a sequence with at least95% identity to SEQ ID NO: 15, wherein said nucleic acid sequence comprises a sequence having at least 95% sequence identity to at least one of SEQ ID NO:23 and SEQ ID NO:25.
41. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 1 .
42. The method of claim 41 , wherein the cells are SF9 cells.
43. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 2 .
44. The method of claim 43 , wherein the cells are SF9 cells.
45. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 3 .
46. The method of claim 45 , wherein the cells are SF9 cells.
47. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 4 .
48. The method of claim 47 , wherein the cells are SF9 cells.
49. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 5 .
50. The method of claim 49 , wherein the cells are SF9 cells.
51. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 6 .
52. The method of claim 51 , wherein the cells are SF9 cells.
53. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 7 .
54. The method of claim 53 , wherein the cells are SF9 cells.
55. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 8 .
56. The method of claim 55 , wherein the cells are SF9 cells.
57. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vivo, comprising administering the vector of claim 1 to a mammal.
58. The method of claim 57 , wherein the mammal is a pig.
59. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vivo, comprising administering the vector of claim 2 to a mammal.
60. The method of claim 59 , wherein the mammal is a pig.
61. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vivo, comprising administering the vector of claim 3 to a mammal.
62. The method of claim 61 , wherein the mammal is a pig.
63. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vivo, comprising administering the vector of claim 4 to a mammal.
64. The method of claim 63 , wherein the mammal is a pig.
65. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vivo, comprising administering the vector of claim 5 to a mammal.
66. The method of claim 65 , wherein the mammal is a pig.
67. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vivo, comprising administering the vector of claim 6 to a mammal.
68. The method of claim 67 , wherein the mammal is a pig.
69. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vivo, comprising administering the vector of claim 7 to a mammal.
70. The method of claim 69 , wherein the mammal is a pig.
71. A method for expressing the open reading frames of a porcine circovirus type B (PCVB) in vivo, comprising administering the vector of claim 8 to a mammal.
72. The method of claim 71 , wherein the mammal is a pig.